Oclacitinib modulates IL-2 driven T-cell activation through CD25 regulation: A comparative analysis with prednisolone

Area of Science:

• Immunology
• Veterinary Dermatology

Background:

• Canine atopic dermatitis (cAD) is a T-cell mediated allergic skin disease.
• Human and canine AD share immunological similarities, making canine models valuable for translational research.
• Developing methods to study canine T-cell responses is crucial for therapeutic evaluation.

Purpose of the Study:

• To develop a high-purity canine T-cell isolation protocol.
• To characterize canine T-cell proliferation, activation, and cytokine production in response to oclacitinib (OM) and prednisolone.
• To establish an in vitro platform for assessing immunomodulatory agents in canine models.

Main Methods:

• Isolated canine T-cells and stimulated proliferation using anti-CD3/CD86 and IL-2.
• Assessed T-cell activation markers (CD25) and cytokine secretion (IL-8, KC-like, IL-10, TNFα, GM-CSF).
• Treated T-cells with varying concentrations of oclacitinib (OM) and prednisolone.

Main Results:

• Oclacitinib (OM) demonstrated dose-dependent reductions in CD25 expression and frequency on activated T-cells.
• Prednisolone treatment resulted in increased CD25 expression, similar to control groups.
• OM showed a trend towards reduced secretion of IL-8, KC-like, and IL-10, with no significant impact on TNFα, GM-CSF, or cell viability.

Conclusions:

• Oclacitinib (OM) and prednisolone exhibit distinct immunomodulatory effects on canine T-cells in vitro.
• The developed canine T-cell model provides a robust platform for future research on cAD therapies.
• Findings support the use of OM as a targeted immunomodulator for canine atopic dermatitis.